Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: June 28, 2008 (Fiscal Year 2008)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an intelligent robotic radiosurgery system used to treat solid tumors anywhere in the body. The system combines continuous image-guidance technology with a compact linear accelerator to deliver precise, high-dose radiation without the need for invasive surgery or rigid frames. As of June 30, 2008, 140 systems were installed globally (90 in the Americas, 38 in Asia, 12 in Europe).
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 | Fiscal 2006 |
|---|---|---|---|
| Net Revenue | $210.4 million | $140.5 million | $52.9 million |
| Gross Profit | $107.0 million | $80.0 million | $25.4 million |
| Gross Margin | 50.8% | 57.0% | 48.0% |
| Net Income (Loss) | $5.4 million | ($5.6) million | ($33.7) million |
| Diluted EPS | $0.09 | ($0.18) | ($2.11) |
| Operating Cash Flow | ($18.0) million | $11.6 million | $22.1 million |
| Cash & Equivalents | $36.9 million | $204.8 million | $27.9 million |
| Total Assets | $295.0 million | $332.1 million | $138.6 million |
| Deferred Revenue | $114.2 million | $154.3 million | $149.7 million |
| Accumulated Deficit | ($121.1) million | ($126.3) million | ($120.6) million |
Note: The company reported its first full year of net income since inception in Fiscal 2008.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 50% to $210.4 million, driven primarily by the sale of 12 CyberKnife systems previously under the shared ownership program ($23.7 million) and the recognition of $13.1 million in product revenue from units previously shipped to a distributor in China.
- Profitability: The company transitioned from a net loss of $5.6 million in 2007 to a net income of $5.4 million in 2008. This was aided by a significant increase in interest and other income ($7.2 million vs. $3.5 million in 2007) due to higher cash balances from the 2007 IPO.
- Gross Margin Compression: Gross margin decreased to 50.8% from 57.0% in 2007. Management attributed this to the lower-margin nature of sales from the shared ownership program and increased shipments through distributor channels.
- Cash Position: Cash and cash equivalents decreased by $167.9 million to $36.9 million. This decline was due to cash used in operating activities ($18.0 million), stock repurchases ($24.0 million), and the investment of excess cash into short-term and long-term investments ($122.6 million total).
- Backlog: Total backlog stood at approximately $647.0 million as of June 30, 2008, with $459.7 million classified as non-contingent.
Guidance, Outlook, Risks, and Unusual Items
- Internal Control Material Weakness: Management and the independent auditor (Grant Thornton LLP) identified a material weakness in internal control over financial reporting related to the accounting for revenue transactions. This resulted in an adverse opinion on internal controls, though the financial statements received an unqualified opinion. Remediation efforts include hiring additional finance personnel and strengthening revenue recognition procedures.
- Investment Liquidity Risk: The company holds $21.5 million in Auction Rate Securities (ARS). Due to failed auctions in the credit markets, these investments are currently illiquid and classified as long-term. The company recorded a temporary decline in fair value of $0.9 million.
- Reimbursement Uncertainty: The company faces risks regarding Medicare reimbursement rates. Proposed rates for 2009 suggest a decrease in payment for initial treatments compared to 2008. Additionally, new Stark Law regulations effective October 2009 may require restructuring of physician-owned entities, potentially impacting sales.
- Regulatory Approvals: The company received full-body treatment approval in Japan in June 2008, expanding its market potential there. However, sales to public civilian hospitals in China remain constrained pending Ministry of Health review.
- Stock Repurchase: The company repurchased 2.14 million shares for approximately $24.0 million during the fiscal year under a $25.0 million program.
Key Facts for Investor Verification
- Revenue Recognition Complexity: Verify the company's ability to remediate the material weakness in revenue recognition controls, given the complex mix of product sales, service plans, and shared ownership arrangements.
- Liquidity of ARS Investments: Monitor the status of the $21.5 million in illiquid Auction Rate Securities and the potential for future impairment charges if the decline in value is deemed other-than-temporary.
- Reimbursement Trends: Track final Medicare reimbursement rates for 2009 and the impact of new Stark Law regulations on physician-owned CyberKnife centers.
- Backlog Conversion: Assess the conversion rate of the $647 million backlog into recognized revenue, noting that a significant portion ($187.3 million) is contingent on regulatory approvals or financing.
- Operating Cash Flow: Observe the reversal of negative operating cash flow in 2008, which was driven by increases in accounts receivable and inventory, to ensure future cash generation aligns with net income.